{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:15:56Z","timestamp":1791353756779,"version":"4.3.1"},"reference-count":248,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.bone.2011.04.022","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T06:28:40Z","timestamp":1304404120000},"page":"2-19","source":"Crossref","is-referenced-by-count":1000,"title":["Bisphosphonates: The first 40years"],"prefix":"10.1016","volume":"49","author":[{"given":"R. Graham G.","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2011.04.022_bb0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jlac.18651330307","article-title":"Ueber die Einwirkung des Chloracetyls auf phosphorige Saure","volume":"133","author":"Menschutkin","year":"1865","journal-title":"Ann Chem Pharmacol"},{"key":"10.1016\/j.bone.2011.04.022_bb0010","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/cber.189703002157","article-title":"Acetodiphosphorige Saure","volume":"20","author":"Von Baeyer","year":"1897","journal-title":"Berichte Dtsch Chem Ges"},{"key":"10.1016\/j.bone.2011.04.022_bb0015","series-title":"Bisphosphonates on bone","first-page":"111","article-title":"Discovery and history of the non-medical uses of bisphosphonates. Chapter 7","author":"Blomen","year":"1995"},{"key":"10.1016\/j.bone.2011.04.022_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0025","series-title":"Bisphosphonates in bone disease. From the laboratory to the patient","author":"Fleisch","year":"2000"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"issue":"Suppl 4","key":"10.1016\/j.bone.2011.04.022_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2011.04.022_bb0040","first-page":"265","article-title":"Bisphosphonates: structure\u2013activity relationships and therapeutic implications","volume":"8","author":"Geddes","year":"1994","journal-title":"Bone Miner Res"},{"issue":"2","key":"10.1016\/j.bone.2011.04.022_bb0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0050","doi-asserted-by":"crossref","unstructured":"Roelofs AJ, Ebetino FH, Reska AA, Russell R.G.G, Rogers MJ. Bisphosphonates. Mechanisms of Action. Chapter 81 In 'Principles of Bone Biology' 3rd edition, San Diego: Academic Press, Ed Bilizekian J; 2008.","DOI":"10.1016\/B978-0-12-373884-4.00095-1"},{"key":"10.1016\/j.bone.2011.04.022_bb0055","series-title":"Bisphosphonates on bone","year":"1995"},{"key":"10.1016\/j.bone.2011.04.022_bb0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.04.022_bb0065","series-title":"The chemical dynamics of bone mineral","isbn-type":"print","author":"Neuman","year":"1958","ISBN":"https:\/\/id.crossref.org\/isbn\/0226575128"},{"key":"10.1016\/j.bone.2011.04.022_bb0070","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1152\/ajplegacy.1961.200.6.1296","article-title":"Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase","volume":"200","author":"Fleisch","year":"1961","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bone.2011.04.022_bb0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1152\/ajplegacy.1962.203.4.671","article-title":"Isolation from urine of pyrophosphate, a calcification inhibitor","volume":"203","author":"Fleisch","year":"1962","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bone.2011.04.022_bb0080","first-page":"51","article-title":"The urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculus","volume":"31","author":"Russell","year":"1966","journal-title":"Clin Sci"},{"key":"10.1016\/j.bone.2011.04.022_bb0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(65)91422-4","article-title":"Excretion of inorganic pyrophosphate in hypophosphatasia","volume":"ii","author":"Russell","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2011.04.022_bb0090","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI106589","article-title":"Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta and other disorders of bone","volume":"50","author":"Russell","year":"1971","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0095","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/212901a0","article-title":"Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis","volume":"212","author":"Fleisch","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.bone.2011.04.022_bb0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/bj1400175","article-title":"The uptake and metabolism of 32P-pyrophosphate by mouse calvaria in vitro","volume":"140","author":"Jung","year":"1974","journal-title":"Biochem J"},{"issue":"4","key":"10.1016\/j.bone.2011.04.022_bb0105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1748-1716.2009.01957.x","article-title":"Evolutionary origins of the purinergic signalling system","volume":"195","author":"Burnstock","year":"2009","journal-title":"Acta Physiol (Oxf)"},{"issue":"3","key":"10.1016\/j.bone.2011.04.022_bb0110","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.coph.2010.01.003","article-title":"Purinergic signalling and bone remodelling","volume":"10","author":"Orriss","year":"2010","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.bone.2011.04.022_bb0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrrheum.2010.182","article-title":"Pathophysiology of articular chondrocalcinosis\u2014role of ANKH","volume":"7","author":"Abhishek","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1210\/jc.2010-2614","article-title":"It ANKH necessarily so","volume":"96","author":"Collins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0125","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.2001.281.1.C1","article-title":"Inorganic pyrophosphate generation and disposition in pathophysiology","volume":"281","author":"Terkeltaub","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.bone.2011.04.022_bb0130","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0002-9440(10)62481-9","article-title":"Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase\/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice","volume":"166","author":"Anderson","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bone.2011.04.022_bb0135","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/rheumatology\/41.7.725","article-title":"Genetic studies of disorders of calcium crystal deposition","volume":"41","author":"Timms","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.bone.2011.04.022_bb0140","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1359\/jbmr.2001.16.9.1724","article-title":"Hypophosphatasia: molecular diagnosis of Rathbun's original case","volume":"16","author":"Mumm","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1016\/j.bone.2011.04.022_bb0145","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1359\/jbmr.1999.14.12.2015","article-title":"Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia","volume":"14","author":"Fedde","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.bone.2011.04.022_bb0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1098-1004(200004)15:4<309::AID-HUMU2>3.0.CO;2-C","article-title":"Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene","volume":"15","author":"Mornet","year":"2000","journal-title":"Hum Mutat"},{"key":"10.1016\/j.bone.2011.04.022_bb0155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1749-6632.2010.05387.x","article-title":"Physiological role of alkaline phosphatase explored in hypophosphatasia","volume":"1192","author":"Whyte","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bone.2011.04.022_bb0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/humu.9297","article-title":"The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI)","volume":"25","author":"Ruf","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.bone.2011.04.022_bb0165","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s004390050993","article-title":"Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL)","volume":"104","author":"Nakamura","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.bone.2011.04.022_bb0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1126\/science.289.5477.265","article-title":"Role of the mouse ank gene in control of tissue calcification and arthritis","volume":"289","author":"Ho","year":"2000","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bone.2011.04.022_bb0175","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1086\/343053","article-title":"Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH","volume":"71","author":"Williams","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.bone.2011.04.022_bb0180","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/art.20978","article-title":"Association of sporadic chondrocalcinosis with a \u22124-basepair G-to-A transition in the 5\u2032-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate","volume":"52","author":"Zhang","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2011.04.022_bb0185","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1086\/343054","article-title":"Mutations in ANKH cause chondrocalcinosis","volume":"71","author":"Pendleton","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.bone.2011.04.022_bb0190","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1086\/320612","article-title":"Autosomal dominant craniometaphyseal dysplasia is caused mutations in the transmembrane protein ANK","volume":"68","author":"Reichenberger","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.bone.2011.04.022_bb0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/ng0501-37","article-title":"Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia","volume":"28","author":"Nuernberg","year":"2001","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.bone.2011.04.022_bb0200","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ajmg.a.33826","article-title":"Craniometaphyseal dysplasia with severe craniofacial involvement shows homozygosity at 6q21-22.1 locus","volume":"155","author":"Prontera","year":"2011","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0205","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2010-1539","article-title":"Autosomal recessive mental retardation, deafness, ankylosis, and mild hypophosphatemia associated with a novel ANKH mutation in a consanguineous family","volume":"96","author":"Morava","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymgme.2011.01.018","article-title":"Vascular pathology of medial arterial calcifications in NT5E deficiency: implications for the role of adenosine in pseudoxanthoma elasticum","volume":"103","author":"Markello","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.bone.2011.04.022_bb0215","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa0912923","article-title":"NT5E mutations and arterial calcifications","volume":"364","author":"St Hilaire","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb0220","first-page":"363","article-title":"Inhibition by pyrophosphate of aortic calcification induced by Vitamin D3 in rats","volume":"35","author":"Schibler","year":"1968","journal-title":"Clin Sci"},{"key":"10.1016\/j.bone.2011.04.022_bb0225","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF02547227","article-title":"The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals","volume":"11","author":"Jung","year":"1973","journal-title":"Calcif Tissue Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2362.1970.tb00591.x","article-title":"The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo","volume":"1","author":"Fleisch","year":"1970","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0235","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF02547219","article-title":"Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats","volume":"11","author":"Schenk","year":"1973","journal-title":"Calcif Tissue Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0240","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3181\/00379727-122-31123","article-title":"Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis","volume":"122","author":"Fleisch","year":"1966","journal-title":"Proc Soc Exp Biol"},{"key":"10.1016\/j.bone.2011.04.022_bb0245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF02196199","article-title":"The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats","volume":"6","author":"Russell","year":"1970","journal-title":"Calcif Tissue Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0250","doi-asserted-by":"crossref","first-page":"10-10A","DOI":"10.1007\/BF02065192","article-title":"The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo","volume":"2","author":"Fleisch","year":"1968","journal-title":"Calcif Tissue Res"},{"issue":"3","key":"10.1016\/j.bone.2011.04.022_bb0255","first-page":"CR345-6","article-title":"Influence of diphosphonates on the deposition and dissolution of calcium phosphate in vitro and in vivo","volume":"26","author":"Fleisch","year":"1968","journal-title":"Helv Physiol Pharmacol Acta"},{"key":"10.1016\/j.bone.2011.04.022_bb0260","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.165.3899.1264","article-title":"Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo","volume":"165","author":"Francis","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.bone.2011.04.022_bb0265","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02546591","article-title":"The effect of phosphonates on dental enamel in vitro and calculus formation in vivo","volume":"11","author":"Francis","year":"1973","journal-title":"Calcif Tissue Res"},{"issue":"2","key":"10.1016\/j.bone.2011.04.022_bb0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF02058658","article-title":"The inhibition of calcium hydroxypatite crystal growth by polyphosphonates and polyphosphates","volume":"3","author":"Francis","year":"1969","journal-title":"Calcif Tissue Res"},{"issue":"2","key":"10.1016\/j.bone.2011.04.022_bb0280","first-page":"69","article-title":"Optimization of the ratio of stannous tin: ethane-1-hydroxy-1, 1-diphosphonate for bone scanning with 99mTc-pertechnetate","volume":"15","author":"Tofe","year":"1974","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bone.2011.04.022_bb0285_1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2362.1971.tb00640.x","article-title":"The effects of diphosphonates, polyphosphates and calcitonin on immobilisation osteoporosis in rats","volume":"1","author":"Muehlbauer","year":"1971","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0285_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/223211a0","article-title":"Prevention by a diphosphonate of immobilisation 'osteoporosis' in rats","volume":"223","author":"Fleisch","year":"1969","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2011.04.022_bb0290","first-page":"S63","article-title":"Effects of clodronate on immobilization bone loss","volume":"8","author":"Minaire","year":"1987","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0295","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF02547219","article-title":"Effect of two diphosphonates on bone and cartilage growth and resorption in the tibial epiphysis and metaphysis of rats","volume":"11","author":"Schenk","year":"1973","journal-title":"Calcif Tissue Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0300","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02555748","article-title":"Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat","volume":"38","author":"Schenk","year":"1986","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2011.04.022_bb0305","first-page":"S443","article-title":"Bisphosphonate affinity to hydroxyapatite and farnesyl pyrophosphate inhibitory potency together drive in vivo efficacy","volume":"22","author":"Lundy","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1042\/cs0430031","article-title":"The influence of two diphosphonates on calcium metabolism in the rat","volume":"43","author":"Gasser","year":"1972","journal-title":"Clin Sci"},{"key":"10.1016\/j.bone.2011.04.022_bb0315","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1172\/JCI113257","article-title":"Hypercalcaemia induced with an arotinoid in thyroparathyroidectomised rats. a new model to study bone resorption in vivo","volume":"80","author":"Trechsel","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0320","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF02556639","article-title":"Short and long term effects of a single dose of bisphosphonates on retibnoid-induced bone resorption in thyroparathyroidectomised rats","volume":"43","author":"Stutzer","year":"1988","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2011.04.022_bb0325","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"Muehlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0330","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1021\/jm020819i","article-title":"Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)","volume":"45","author":"Widler","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bone.2011.04.022_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2011.01.014","article-title":"Pharmacology of bisphosphonates","author":"Cremers","year":"2011","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2011.04.022_bb0340","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF02556218","article-title":"Sodium EDTA enhances intestinal absorption of two bisphosphonates","volume":"49","author":"Janner","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2011.04.022_bb0345","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"355","author":"DeGroen","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb0350","first-page":"325","article-title":"Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis","volume":"6","author":"Pazianas","year":"2010","journal-title":"Ther Clin Risk Manage"},{"issue":"6","key":"10.1016\/j.bone.2011.04.022_bb0355","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00223-010-9364-1","article-title":"Adverse effects of bisphosphonates","volume":"86","author":"Abrahamsen","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"10.1016\/j.bone.2011.04.022_bb0360","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1016\/j.bone.2011.04.022_bb0365","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1210\/jc.2010-1571","article-title":"Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis","volume":"95","author":"Abrahamsen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.04.022_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2011.01.003","article-title":"Safety of bisphosphonates","author":"Pazianas","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2010.12.024","article-title":"The kidney and bisphosphonates","author":"Miller","year":"2011","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2011.04.022_bb0380","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2032446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0385","series-title":"Bisphosphonates on bone","article-title":"Effects of bisphosphonates on bone biomechanics. Chapter 31","author":"Ferretti","year":"1995"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2005.03.017","article-title":"The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover","volume":"37","author":"Borah","year":"2005","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2011.04.022_bb0395","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF01320915","article-title":"Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties","volume":"53","author":"Guy","year":"1993","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.bone.2011.04.022_bb0400","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02672503","article-title":"Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats","volume":"8","author":"Lalla","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.04.022_bb0405","first-page":"2200","article-title":"Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bone.2011.04.022_bb0410","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.04.022_bb0415","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2005-0057","article-title":"Long-term safety of bisphosphonates","volume":"90","author":"Ott","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl","key":"10.1016\/j.bone.2011.04.022_bb0420","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF03026321","article-title":"The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib","volume":"23","author":"Mashiba","year":"2005","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.bone.2011.04.022_bb0425","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"4\u20135","key":"10.1016\/j.bone.2011.04.022_bb0430","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0221-8747(81)90045-X","article-title":"The long-term skeletal effects of EHDP in dogs","volume":"3","author":"Flora","year":"1981","journal-title":"Metab Bone Dis Relat Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0435","article-title":"Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know","author":"Allen","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0440","article-title":"Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate","author":"Allen","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0445","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vascn.2003.11.003","article-title":"New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate","volume":"50","author":"Bauss","year":"2004","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.bone.2011.04.022_bb0450","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1302\/0301-620X.87B3.14665","article-title":"Zoledronic acid causes enhancement of bone growth into porous implants","volume":"87","author":"Bobyn","year":"2005","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.bone.2011.04.022_bb0455","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1359\/JBMR.050712","article-title":"Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model","volume":"20","author":"Little","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2011.01.009","article-title":"Bisphosphonates in orthopedic applications","author":"Wilkinson","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.orthres.2004.06.004","article-title":"Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial","volume":"23","author":"Wilkinson","year":"2005","journal-title":"J Orthop Res"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0470","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17453670902807466","article-title":"Bisphosphonates and implants. An overview","volume":"80","author":"Aspenberg","year":"2009","journal-title":"Acta Orthop"},{"issue":"4","key":"10.1016\/j.bone.2011.04.022_bb0475","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1902\/jop.2009.090587","article-title":"Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review","volume":"81","author":"Javed","year":"2010","journal-title":"J Periodontol"},{"key":"10.1016\/j.bone.2011.04.022_bb0480","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2004.12.017","article-title":"The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats","volume":"37","author":"Kurth","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0485","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1359\/jbmr.2003.18.7.1300","article-title":"Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis","volume":"18","author":"Little","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0490","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1359\/jbmr.2003.18.11.2016","article-title":"Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats","volume":"18","author":"Little","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.bone.2011.04.022_bb0495","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2106\/JBJS.D.02959","article-title":"The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study","volume":"87","author":"Lai","year":"2005","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.bone.2011.04.022_bb0500","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.orthres.2004.11.015","article-title":"Zoledronic acid improves femoral head sphericity in a rat model of Perthes disease","volume":"23","author":"Little","year":"2005","journal-title":"J Orthop Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0505","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02408534","article-title":"Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats","volume":"32","author":"Reitsma","year":"1980","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2011.04.022_bb0510","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.04.022_bb0515","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.04.022_bb0520","first-page":"41S","article-title":"Long-term protective effect of a single IV injection of zoledronic acid on cancellous bone structure and cortical bone in ovariectomized rats","volume":"30","author":"Gasser","year":"2002","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2011.04.022_bb0525","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/jm0303709","article-title":"Quantitative structure\u2013activity relationships for gammadelta T cell activation by bisphosphonates","volume":"47","author":"Sanders","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bone.2011.04.022_bb0530","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1359\/JBMR.0301230","article-title":"Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro","volume":"19","author":"Thompson","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2011.03.774","article-title":"The relationship between the chemistry and biological activity of the bisphosphonates","author":"Ebetino","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0540","series-title":"Bisphosphonate on bones","article-title":"Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies","author":"Ebrahimpour","year":"1995"},{"key":"10.1016\/j.bone.2011.04.022_bb0545","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"18","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0550","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jbm.b.31500","article-title":"Differences between bisphosphonates in binding affinities for hydroxyapatite","volume":"92","author":"Lawson","year":"2010","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"3","key":"10.1016\/j.bone.2011.04.022_bb0555","first-page":"E298","article-title":"Relation between bone mineralization, Ca absorption, and plasma Ca in phosphonate-treated rats","volume":"232","author":"Trechsel","year":"1977","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bone.2011.04.022_bb0560","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02405012","article-title":"Structure\u2013activity relationships of various bisphosphonates","volume":"35","author":"Shinoda","year":"1983","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2011.04.022_bb0565","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/jbmr.5650040518","article-title":"Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate","volume":"4","author":"Papapoulos","year":"1988","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0570","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00002512-199813010-00008","article-title":"Risedronate","volume":"13","author":"Goa","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bone.2011.04.022_bb0575","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2032446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0580","first-page":"217","article-title":"Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity","volume":"109\/110","author":"Ebetino","year":"1996","journal-title":"Phosphorus Sulfur Silicon"},{"key":"10.1016\/j.bone.2011.04.022_bb0585","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0590","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0169-6009(89)90021-4","article-title":"Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone","volume":"6","author":"Flanagan","year":"1986","journal-title":"Bone Miner"},{"key":"10.1016\/j.bone.2011.04.022_bb0595","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s002239900505","article-title":"Comparison of the cytotoxic effects of bisphosphnates in vitro and in vivo","volume":"63","author":"Ito","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2011.04.022_bb0600","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0169-6009(89)90021-4","article-title":"Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone","volume":"6","author":"Flanagan","year":"1989","journal-title":"Bone Miner"},{"key":"10.1016\/j.bone.2011.04.022_bb0605","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1359\/jbmr.1998.13.11.1721","article-title":"Human osteoclast formation and activity in vitro: effects of alendronate","volume":"13","author":"Breuil","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0610","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0615","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0026-895X(25)09541-0","article-title":"Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages","volume":"50","author":"Selander","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bone.2011.04.022_bb0620","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S8756-3282(95)00150-6","article-title":"A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders","volume":"17","author":"Murakami","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0625","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","article-title":"Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow","volume":"83","author":"Hughes","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0630","first-page":"27","article-title":"Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix","volume":"1","author":"Boonekamp","year":"1986","journal-title":"Bone Miner"},{"key":"10.1016\/j.bone.2011.04.022_bb0635","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jbmr.5650030210","article-title":"Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate","volume":"3","author":"L\u00f6wik","year":"1988","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0640","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/8756-3282(96)00182-2","article-title":"Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones","volume":"19","author":"Masarachia","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0645","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/8756-3282(94)00035-X","article-title":"Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models","volume":"16","author":"Azuma","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0650","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jbmr.5650050107","article-title":"Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy","volume":"5","author":"Sato","year":"1990","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.bone.2011.04.022_bb0655","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2010","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0660","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bone.2011.04.022_bb0665","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect","volume":"26","author":"Eisman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0670","article-title":"Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability","author":"Bellido","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0675","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0680","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1074\/jbc.M412817200","article-title":"Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation","volume":"280","author":"Plotkin","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2011.04.022_bb0685","article-title":"A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice","author":"Plotkin","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0690","doi-asserted-by":"crossref","unstructured":"Sugiyama T, Meakin LB, Galea GL, Jackson BF, Lanyon LE, Ebetino FH, Russell RGG, Price JS. Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone this issue.","DOI":"10.1016\/j.bone.2011.03.775"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0695","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1042\/bj1720097","article-title":"The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture","volume":"172","author":"Fast","year":"1978","journal-title":"Biochem J"},{"key":"10.1016\/j.bone.2011.04.022_bb0700","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/jbmr.5650111017","article-title":"The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+ ATPase","volume":"11","author":"David","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0705","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI114459","article-title":"Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro","volume":"85","author":"Carano","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0710","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1172\/JCI118283","article-title":"Acid extrusion is induced by osteoclast attachment to bone","volume":"96","author":"Zimolo","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0715","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0006-2952(97)00225-6","article-title":"Alendronate inhibition of protein-tyrosine-phosphatase-Meg1","volume":"54","author":"Olpas","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bone.2011.04.022_bb0720","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S8756-3282(97)00025-2","article-title":"Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts","volume":"20","author":"Murakami","year":"1997","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0725","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0005-2744(76)90291-6","article-title":"The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes","volume":"429","author":"Felix","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bone.2011.04.022_bb0730","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/8756-3282(87)90018-4","article-title":"Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro","volume":"8","author":"Lerner","year":"1987","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0735","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/8756-3282(95)00426-2","article-title":"Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures","volume":"18","author":"Niskikawa","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0740","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S8756-3282(96)00184-6","article-title":"Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106","volume":"19","author":"Yu","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0745","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1172\/JCI116422","article-title":"Bisphosphonates act on rat bone resorption through the mediation of osteoblasts","volume":"91","author":"Sahni","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2011.04.022_bb0750","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1210\/endo.137.6.8641182","article-title":"Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption","volume":"137","author":"Vitte","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2011.04.022_bb0755","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","article-title":"From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates","volume":"75","author":"Rogers","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2011.04.022_bb0760","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/jbmr.5650090710","article-title":"Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum","volume":"9","author":"Rogers","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0765","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0026-895X(25)08553-0","article-title":"Structure\u2013activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae","volume":"47","author":"Rogers","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bone.2011.04.022_bb0770","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1042\/bj3030303","article-title":"Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum","volume":"303","author":"Rogers","year":"1994","journal-title":"Biochem J"},{"key":"10.1016\/j.bone.2011.04.022_bb0775","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/0006-291X(92)91574-A","article-title":"Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum","volume":"189","author":"Rogers","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bone.2011.04.022_bb0780","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","author":"Rogers","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0785","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1006\/bbrc.1996.1113","article-title":"Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes","volume":"224","author":"Rogers","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bone.2011.04.022_bb0790","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/0006-2952(92)90342-G","article-title":"Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum","volume":"44","author":"Pelorgeas","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bone.2011.04.022_bb0795","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-b, g-dichloromethylene) triphosphate, by mammalian cells in vitro","volume":"12","author":"Frith","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0800","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0378-4347(97)00490-8","article-title":"Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography\u2013electrospray mass spectrometry","volume":"704","author":"Auriola","year":"1997","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.bone.2011.04.022_bb0805","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E","article-title":"The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis","volume":"44","author":"Frith","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2011.04.022_bb0810","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1023\/A:1012157212793","article-title":"Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake","volume":"14","author":"Rogers","year":"1997","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.bone.2011.04.022_bb0815","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/mol.61.5.1255","article-title":"Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP\/ATP translocase by a nonhydrolyzable, adenine-containing metabolite","volume":"61","author":"Lehenkari","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bone.2011.04.022_bb0820","first-page":"759","article-title":"1-hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase","volume":"46","author":"Amin","year":"1996","journal-title":"Drug Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0825","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","article-title":"Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis","volume":"33","author":"Amin","year":"1992","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0830","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"issue":"7","key":"10.1016\/j.bone.2011.04.022_bb0835","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrd2221","article-title":"Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets","volume":"6","author":"Konstantinopoulos","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bone.2011.04.022_bb0840","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0092-8674(92)90163-7","article-title":"The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors","volume":"70","author":"Ridley","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bone.2011.04.022_bb0845","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0092-8674(92)90164-8","article-title":"The small GTP-binding protein, rac, regulates growth factor-induced membrane ruffling","volume":"70","author":"Ridley","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bone.2011.04.022_bb0850","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0955-0674(93)90130-I","article-title":"Rab GTPases in vesicular transport","volume":"5","author":"Zerial","year":"1993","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.bone.2011.04.022_bb0855","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1242\/jcs.108.6.2285","article-title":"The small GTP-binding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts","volume":"108","author":"Zhang","year":"1995","journal-title":"J Cell Sci"},{"key":"10.1016\/j.bone.2011.04.022_bb0860","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0865","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1359\/jbmr.1998.13.11.1668","article-title":"Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure\u2013activity relationships in J774 macrophages","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0870","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro","volume":"96","author":"Fisher","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bone.2011.04.022_bb0875","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.0224","article-title":"Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase\/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo","volume":"255","author":"van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bone.2011.04.022_bb0880","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure\u2013activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bone.2011.04.022_bb0885","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.bone.2011.04.022_bb0890","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1359\/jbmr.2003.18.1.88","article-title":"The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity","volume":"18","author":"Staal","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0895","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1126\/science.279.5350.509","article-title":"Rho GTPases and the actin cytoskeleton","volume":"279","author":"Hall","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bone.2011.04.022_bb0900","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1302\/0301-620X.58B1.818090","article-title":"Myositis ossificans progressiva. Clinical features of eight patients and their response to treatment","volume":"58-B","author":"Smith","year":"1976","journal-title":"J Bone Joint Surg"},{"key":"10.1016\/j.bone.2011.04.022_bb0905","series-title":"Bisphosphonate on bones","article-title":"Ectopic calcification and ossification. Chapter 31","author":"Smith","year":"1995"},{"issue":"6","key":"10.1016\/j.bone.2011.04.022_bb0910","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3109\/17453677408989703","article-title":"Effect of a diphosphonate on para-articular ossification after total hip replacement","volume":"45","author":"Bijvoet","year":"1974","journal-title":"Acta Orthop Scand"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2011.04.022_bb0915","first-page":"S63","article-title":"Effects of clodronate on immobilization bone loss","volume":"8","author":"Minaire","year":"1987","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0920","first-page":"270","article-title":"The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease","volume":"19","author":"Fogelman","year":"1978","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bone.2011.04.022_bb0925","series-title":"Bone scanning in clinical practice","first-page":"1","article-title":"99mTc-diphosphonate uptake mechanisms on bone","author":"Francis","year":"1987"},{"key":"10.1016\/j.bone.2011.04.022_bb0930","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(71)91447-4","article-title":"Diphosphonates and Paget's disease of bone","volume":"i","author":"Smith","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2011.04.022_bb0935","first-page":"894","article-title":"Diphosphonates in Paget's disease","volume":"1","author":"Russell","year":"1974","journal-title":"Lancet"},{"issue":"8120","key":"10.1016\/j.bone.2011.04.022_bb0940","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(79)91318-7","article-title":"Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)","volume":"1","author":"Frijlink","year":"1979","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bone.2011.04.022_bb0945","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/art.1780231015","article-title":"Use of etidronate (EHDP) in Paget's disease of bone","volume":"23","author":"Johnston","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2011.04.022_bb0950","series-title":"Proc. symp on diphosphonates and Paget's disease of bone, York","first-page":"219","article-title":"Paget's disease of bone: diagnosis and management","volume":"3","author":"Kanis","year":"1981"},{"key":"10.1016\/j.bone.2011.04.022_bb0955","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJM199702203360807","article-title":"The management of Paget's disease of bone","volume":"336","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bone.2011.04.022_bb0960","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jcem-54-4-837","article-title":"Long term effects of dichloromethylene diphosphonate in Paget's disease of bone","volume":"54","author":"Delmas","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"issue":"8141","key":"10.1016\/j.bone.2011.04.022_bb0965","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(79)91551-4","article-title":"Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone","volume":"2","author":"Meunier","year":"1979","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bone.2011.04.022_bb0970","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease","volume":"353","author":"Reid","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bone.2011.04.022_bb0975","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.103","article-title":"Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial","volume":"25","author":"Grey","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb0980_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","article-title":"Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate","volume":"22","author":"Hosking","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.bone.2011.04.022_bb0980_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1359\/jbmr.061001e","volume":"22","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb0985","article-title":"Bisphosphonates in Paget's disease","author":"Reid","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb0990","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1983.tb02074.x","article-title":"The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma","volume":"54","author":"Paterson","year":"1983","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bone.2011.04.022_bb0995","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI109780","article-title":"Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases","volume":"65","author":"Chapuy","year":"1980","journal-title":"J Clin Invest"},{"issue":"8120","key":"10.1016\/j.bone.2011.04.022_bb1000","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(79)91319-9","article-title":"Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)","volume":"1","author":"van Breukelen","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2011.04.022_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2011.02.003","article-title":"Bisphosphonates in oncology","author":"Coleman","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb1010","article-title":"Bisphosphonates in preclinical bone oncology","author":"Cl\u00e9zardin","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb1015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb1020","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"Storm","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb1025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/rheumatology\/37.1.87","article-title":"Use of cyclical etidronate and prevention of non-vertebral fractures","volume":"37","author":"van Staa","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.bone.2011.04.022_bb1030","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb1035","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2011.04.022_bb1040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb1045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.bone.2011.04.022_bb1050","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb1055","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"18","key":"10.1016\/j.bone.2011.04.022_bb1060","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb1065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1358\/dot.2010.46.1.1437707","article-title":"Minodronate for the treatment of osteoporosis","volume":"46","author":"Kubo","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.bone.2011.04.022_bb1070","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00198-005-1945-x","article-title":"Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies","volume":"16","author":"Boonen","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.04.022_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2011.02.011","article-title":"Bisphosphonates for postmenopausal osteoporosis","author":"Eastell","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.04.022_bb1080","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jocd.2010.01.084","article-title":"BMD response to delayed-release risedronate 35mg once-a-week formulation taken with or without breakfast","volume":"13","author":"McClung","year":"2010","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.bone.2011.04.022_bb1085","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.bone.2011.04.022_bb1090","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb1095","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"33","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb1100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajmg.c.30072","article-title":"Osteogenesis imperfecta, current and future medical treatment","volume":"139","author":"Rauch","year":"2005","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.bone.2011.04.022_bb1105","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zolendronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb1110","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.clinthera.2009.05.009","article-title":"Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials","volume":"31","author":"Machado","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.bone.2011.04.022_bb1115","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2009-0852","article-title":"Effect of osteoporosis treatment on mortality: a meta-analysis","volume":"95","author":"Bolland","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.04.022_bb1120","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.04.022_bb1125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential mediators of the mortality reduction with zoledronic acid after hip fracture","volume":"25","author":"Colon-Emeric","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.04.022_bb1130","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity","volume":"65","author":"Cl\u00e9zardin","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2011.04.022_bb1135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bone.2011.04.022_bb1140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nm1786","article-title":"Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging","volume":"14","author":"Varela","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2011.04.022_bb1145","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","article-title":"Oral bisphosphonate use and breast cancer incidence in postmenopausal women","volume":"28","author":"Chlebowski","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2011.04.022_bb1150","first-page":"4615","article-title":"Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis","volume":"29","author":"Sassa","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bone.2011.04.022_bb1155","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10495-008-0211-z","article-title":"The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis","volume":"13","author":"Sewing","year":"2008","journal-title":"Apoptosis"},{"key":"10.1016\/j.bone.2011.04.022_bb1160","series-title":"37th European symposium on calcified tissues, Glasgow, Scotland","article-title":"Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate \u2014 Danish National Register Based Cohort Study","author":"Pazianas","year":"2010"},{"key":"10.1016\/j.bone.2011.04.022_bb1165","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00198-010-1411-2","article-title":"Oral bisphosphonates are associated with reduced mortality after hip fracture","volume":"22","author":"Beaupre","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.04.022_bb1170","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/jc.2010-2730","article-title":"Osteoporosis medication and reduced mortality risk in elderly women and men","volume":"96","author":"Center","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.04.022_bb1175","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00198-003-1430-3","article-title":"Mortality and morbidity associated with osteoporosis drug treatment following hip fracture","volume":"14","author":"Cree","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.04.022_bb1180","article-title":"Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study","author":"Sambrook","year":"2010","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.bone.2011.04.022_bb1185","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1021\/jm010412y","article-title":"Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents","volume":"45","author":"Szabo","year":"2002","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bone.2011.04.022_bb1190","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1074\/jbc.M109.027235","article-title":"Molecular characterization of a novel geranylgeranyl pyrophosphate synthase from Plasmodium parasites","volume":"286","author":"Artz","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2011.04.022_bb1195","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.chembiol.2008.10.017","article-title":"Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis","volume":"15","author":"Artz","year":"2008","journal-title":"Chem Biol"},{"key":"10.1016\/j.bone.2011.04.022_bb1200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/jm030084x","article-title":"Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo","volume":"47","author":"Ghosh","year":"2004","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bone.2011.04.022_bb1205","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm0002578","article-title":"Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy","volume":"44","author":"Martin","year":"2001","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb1210","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/prot.20754","article-title":"Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design","volume":"62","author":"Gabelli","year":"2005","journal-title":"Proteins"},{"issue":"9","key":"10.1016\/j.bone.2011.04.022_bb1215","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1021\/jm040132t","article-title":"Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations","volume":"48","author":"Ling","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bone.2011.04.022_bb1220","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1006\/bbrc.2001.5009","article-title":"(31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth","volume":"284","author":"Moreno","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.bone.2011.04.022_bb1225","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1086\/341074","article-title":"Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate","volume":"186","author":"Rodriguez","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bone.2011.04.022_bb1230","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1039\/B512310K","article-title":"Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents","volume":"36","author":"Zhang","year":"2007","journal-title":"Chem Soc Rev"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211009690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211009690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T10:21:58Z","timestamp":1741170118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328211009690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":248,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S8756328211009690"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2011.04.022","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}